Group 1 - The company announced that its wholly-owned subsidiary, GoldCupTolyEuropeElectromagneticWires.r.o., signed a purchase agreement with Czech company Solwings.r.o. for a factory at a price of €2,996,000 (excluding VAT) [1] - This agreement marks a significant advancement in the establishment of the company's European production base, laying a solid foundation for future construction and production [1] - The funding for this acquisition will come from the company's own or self-raised funds, and it will not affect the normal operation of its existing main business [1] Group 2 - It is important to note that the effectiveness of the agreement is subject to certain preconditions, and there are uncertainties regarding the release of the factory's mortgage rights and the transfer of ownership [1]

Group 1 - The core viewpoint of the article highlights that Rui Feng Hui Bang, a well-known private equity firm, has conducted research on a listed company, Weili Medical, focusing on its strategies to address domestic medical consumables procurement and the growing demand for overseas production capacity [1] - Weili Medical is actively establishing a factory in Mexico starting in 2024 to meet production needs and is also preparing a second overseas production base in Indonesia, which is expected to complete its first phase of construction and production by the end of this year [1] - The company is developing key products in its anesthesia line, nursing line, and urology field, aiming to launch these products quickly to better meet clinical needs while expanding its product range through technology transformation [1]

Group 1: Financial Performance - In 2024, the company achieved a revenue of 418.96 million CNY, representing a year-on-year growth of 9.98% [3] - The net profit for 2024 was -0.744 million CNY, indicating a loss compared to the previous year [3] - The company plans to distribute cash dividends of 5.00 CNY per 10 shares, totaling approximately 28.76 million CNY, despite the negative net profit [8] Group 2: Cost and Expense Management - Management expenses increased by 45.39% and sales expenses rose by 31.25% in 2024 due to rapid growth in personnel [3] - R&D expenses surged by 94.47%, reflecting the company's commitment to innovation and development [6] Group 3: Market and Business Strategy - The company has a foreign sales ratio of approximately 38%, with no significant impact from current tariff policies on completed orders [2] - The construction of the Thailand factory is progressing as planned, with an expected operational start in 2026 [3] - The company is focusing on expanding its market presence both domestically and internationally, particularly in South America [5] Group 4: Product Development and Innovation - The company is actively developing new products, including dialysis solutions and CRRT products, to enhance its product portfolio [4] - The company has acquired CRRT business assets and plans to complete a comprehensive business ecosystem within three years [4] Group 5: Industry Outlook - The medical device industry, particularly in blood purification, is expected to grow due to increasing global end-stage renal disease patients and supportive national policies [6] - The company remains optimistic about the future of the industry, citing the essential nature of its products and the relatively low impact of market fluctuations [6]